Business Wire

LUNAPHORE-TECHNOLOGIES

Share
Lunaphore deploys COMET™ at Propath UK

Lunaphore , a Swiss life sciences company developing technologies to enable spatial biology in every laboratory, today announced that it has deployed its COMET™ PA instrument at Propath UK , one of Europe’s leading contract research organizations (CRO). Propath UK, a specialist in spatial proteomics and transcriptomics, is the first CRO in Europe to offer COMET™ services to researchers and the first organization to join Lunaphore’s Partner Labs Network, a network of CROs and academic core facilities that offer Lunaphore spatial biology solutions as a service to biopharmaceutical and academic researchers.

COMET™ is a strategic investment for Propath UK to expand its spatial biology service offerings with hyperplex staining and imaging, providing its biopharmaceutical research clients with unprecedented insights from tissue samples to answer biological questions. Lunaphore and Propath UK will work closely to provide a flexible service that meets the needs of researchers across various disciplines.

“We are delighted to form this partnership with Lunaphore and be able to offer our biopharmaceutical clients this highly innovative technology for spatial analysis,” said Dr. Krish Soni, Chief Executive of Propath UK. “We look forward to working closely with Lunaphore to help our clients unlock the incredible potential of hyperplex immunofluorescence through our world-class facility dedicated to spatial biology.”

“My team’s previous experience using COMET™ in a variety of applications at the University of Birmingham allowed us to validate the COMET™’s ability to produce staining results of exceptional quality and reproducibility and provided us the confidence to select Lunaphore as Propath’s hyperplex solution partner,” added Kelly Hunter, Chief Scientific Officer at Propath UK.

COMET™ is a fully automated sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of up to 40 different spatial markers per tissue slide without human intervention. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases.

“We are excited to partner with Propath UK to expand their spatial biology capabilities,” said Ata Tuna Ciftlik, Chief Executive Officer at Lunaphore. “Propath UK is a highly specialized CRO with spatial biology capabilities who can bring spatial biology solutions to BioPharma. We quickly realized that combining the know-how of the Propath UK team and the versatility of COMET™, with its flexible and streamlined panel development capability using validated antibodies, we will be able to bring outstanding results to the end customers.”

To learn more about the COMET™ PA platform, please visit: https://lunaphore.com/products/comet/

To learn more about Lunaphore, please visit: https://lunaphore.com/

To learn more about Propath UK, please visit: https://propath.co.uk

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com .

About Propath UK

Propath UK is a specialist CRO providing research services in molecular pathology, spatial biology and histopathology for the global biopharmaceutical sector. The company offers a range of technologies for spatial proteomic and transcriptomic tissue analysis, including now the Lunaphore COMET™ platform for hyperplex IHC analysis. Propath’s reputation has been gained over the past 40 years by providing a consistent and responsive service across thousands of pre-clinical and clinical studies. To learn more, please visit www.propath.co.uk .

Link:

ClickThru

Social Media:

https://www.facebook.com/lunaphore/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

China’s Top Baijiu Brand Moutai Showcases China's Green Progress in Manufacturing at COP3015.11.2025 17:41:00 CET | Press release

On November 10 local time, the 30th United Nations Climate Change Conference (COP30) opened in Belem, a city in northern Brazil. As one of the activities at the China Pavilion of COP30, the Side Event on Ecological Civilization and Beautiful China Practice was held simultaneously, focusing on ecological civilization, sharing China's experience, and building global consensus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114596036/en/ China Pavilion at COP30 in Belem, Brazil. Addressing the topic of green transformation in traditional industries, You Yalin, Deputy Party Secretary of Kweichow Moutai Co., Ltd., shared the company's green transformation practices and experiences from the perspective of a traditional Chinese liquor producer. “We hope that every bottle of Moutai not only delivers a feast of flavor, but also conveys the idea of harmony between humans and nature. We aim to contribute China's wisdom and Moutai's

Andersen Consulting styrker sine kompetencer inden for digital transformation med Criticalcase14.11.2025 19:44:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer gennem en samarbejdsaftale med Criticalcase, der er et europæisk firma med speciale i cloud-infrastruktur, cybersikkerhed og administrerede it-tjenester. Criticalcase blev grundlagt i 1999 og har hovedsæde i Italien og har markeret sig inden for cloud-sektoren ved at designe og vedligeholde komplekse infrastrukturer for mellemstore og store virksomheder. Gennem skræddersyede løsninger tilbyder virksomheden et omfattende udvalg af tjenester, herunder sikkerhed, overvågning døgnet rundt og systemadministration, hvilket skaber pålidelighed, optimal ydeevne og beskyttelse helt ned til operativsystemniveau. "Vores mission har altid været at guide kunder gennem komplekse teknologiske udfordringer med en strategisk og praktisk tilgang," siger Luca Nunno, der er CEO for Criticalcase. "Samarbejdet med Andersen Consulting giver os mulighed for at få vores ekspertise ud til et bredere globalt publikum og skabe værdi gennem innovation og digital ekspert

Andersen Consulting samarbejder med TruScore14.11.2025 16:15:00 CET | Pressemeddelelse

Andersen Consulting annoncerer en samarbejdsaftale med TruScore, som styrker virksomhedens kompetencer inden for humankapital og hjælper kunder med at opbygge stærkere ledelsesteams og organisatoriske kulturer. Truscore, der har hovedsæde i USA, specialiserer sig i at levere fuldt skræddersyede survey-hosting-løsninger, der gør det muligt for organisationer at gennemføre whitelabel-vurderingsordninger, der er skalerbare, sikre og tilpasset deres specifikke behov. TruScore tilbyder avancerede 360-graders feedbackløsninger og samarbejder med Fortune 500-virksomheder, ledelsesudviklingsfirmaer og uafhængige coaches om at designe og administrere deres egne vurderingsplatforme og -oplevelser. "I nutidens dynamiske forretningsmiljø har organisationer brug for mere end blot en strategi – de har brug for stærk og robust ledelse for at kunne omsætte strategien til succes," siger Derek Murphy, CEO for TruScore. "Gennem dette samarbejde med Andersen Consulting kan vi få vores ekspertise inden for

SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 13:47:00 CET | Press release

-- Advancing Its Overseas Growth Strategy to Expand Japanese-Quality Aesthetic Medicine Across Asia Following Singapore -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in

SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye